You are here: Home Pharmaceuticals in the Environment

Pharmaceuticals in the Environment

Environmental Pollution caused by human and veterinary pharmaceutical substances is an emerging environmental concern.  This roundtable convened a multi-stakeholder group to share insights and discuss responsible business practices.  Speakers included senior executives from Bristol-Myers Squibb, Bayer, ERM, Merck, Travers Smith, AstraZeneca, Boehringer Ingelheim, F. Hoffman-La Roche, Health Care without Harm, Merck Group, Ministry of the Netherlands, Novartis and University of Gothenberg
Roundtable participants agreed that industry‚Äôs best option to tackle the issue is a collaborative approach to increase data transparency, share knowledge, and educate the public about a responsible use of pharmaceuticals, in collaboration with all stakeholders involved in their product stewardship. It was recognized that pharmaceuticals enter the environment via a variety of pathways, many of which are not under the direct control of the pharmaceutical industry.  However, leading pharmaceutical companies treat wastewater from own operations to minimize release of pharmaceuticals to the environment, with excellent results when modern technology is used.  In addition, leading pharmaceutical companies have made commitments to require treatment of wastewater from contract manufacturers/suppliers to minimize release of pharmaceuticals to the environment. 
You can read the event summary here.

WEC thanks Bristol-Myers Squibb for their generous sponsorship of this event.
Document Actions